Published in Am J Med on March 01, 2011
Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov (2011) 1.39
Hypertension in postmenopausal women. Curr Hypertens Rep (2012) 1.07
Abdominal superficial subcutaneous fat: a putative distinct protective fat subdepot in type 2 diabetes. Diabetes Care (2012) 1.00
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis (2012) 0.86
Fatty Acid Oxidation and Cardiovascular Risk during Menopause: A Mitochondrial Connection? J Lipids (2012) 0.85
Testosterone protects female embryonic heart H9c2 cells against severe metabolic stress by activating estrogen receptors and up-regulating IES SUR2B. Int J Biochem Cell Biol (2012) 0.84
Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association. Circulation (2016) 0.83
Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice. Gend Med (2012) 0.81
Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. ScientificWorldJournal (2012) 0.80
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics (2015) 0.80
Implications for reproductive medicine: Sex differences in cardiovascular disease. Sex Reprod Menopause (2011) 0.78
Long-term consequences of estrogens administered in midlife on female cognitive aging. Horm Behav (2015) 0.77
Congress on women's health Trudy Bush lecture 2014: new insights into sex Hormones and Cardiovascular disease. J Womens Health (Larchmt) (2014) 0.77
Estrogen and Cardiovascular Disease: Is Timing Everything? Am J Med Sci (2015) 0.75
DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats. Sci Rep (2017) 0.75
Interviews With Two Women's Health Experts On the Use of Estrogen Therapies. P T (2012) 0.75
Estrogen Replacement Reduces Oxidative Stress in the Rostral Ventrolateral Medulla of Ovariectomized Rats. Oxid Med Cell Longev (2015) 0.75
The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk. Endocrinol Metab Clin North Am (2015) 0.75
Long-Term Hormone Replacement Therapy Is Associated with Low Coronary Artery Calcium Levels in a Cohort of Older Women: The Age, Gene/Environment Susceptibility-Reykjavik Study. J Am Geriatr Soc (2016) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
The path to personalized medicine. N Engl J Med (2010) 9.87
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA (2000) 7.77
The analysis of rates using Poisson regression models. Biometrics (1983) 6.94
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med (2000) 5.17
Postmenopausal hormone therapy and mortality. N Engl J Med (1997) 4.96
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med (2000) 4.84
Molecular and cellular basis of cardiovascular gender differences. Science (2005) 4.37
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med (1989) 3.77
Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med (2003) 3.55
Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 3.49
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation (2000) 3.18
Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA (1997) 3.18
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation (2007) 3.17
Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) (2006) 2.77
Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med (2009) 2.64
Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA (1983) 2.57
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Decreased mortality in users of estrogen replacement therapy. Arch Intern Med (1991) 2.26
Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med (1997) 2.21
Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab (2001) 2.16
Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab (1998) 2.12
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 1.88
The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med (2009) 1.59
Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause (2001) 1.53
Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health (1995) 1.49
Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res (2009) 1.47
Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med (2001) 1.44
Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol (1996) 1.39
Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.32
The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can (2002) 1.27
Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol (1991) 1.07
17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta (1998) 1.07
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost (2001) 1.05
Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med (2001) 1.00
Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Womens Health (Larchmt) (2009) 1.00
Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. Circulation (2004) 0.98
Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol (1995) 0.97
Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation (2001) 0.95
Estrogen stimulation of proinflammatory cytokine and matrix metalloproteinase gene expression in human corneal epithelial cells. Cornea (2005) 0.95
The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial. Thromb Haemost (2001) 0.93
The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril (2004) 0.93
Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab (2001) 0.91
The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis (2005) 0.88
Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab (2006) 0.87
17Beta-estradiol inhibits oxidized low density lipoprotein-induced generation of reactive oxygen species in endothelial cells. Life Sci (2001) 0.87
Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study. J Womens Health (Larchmt) (2004) 0.85
Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol (1999) 0.84
Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol (2002) 0.83
Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J Intern Med (2001) 0.83
Post menopausal hormone replacement therapy and risk of acute myocardial infarction--a case control study of women in the East Midlands, UK. Eur Heart J (2003) 0.83
The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus. Vascul Pharmacol (2002) 0.82
Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost (2000) 0.81
Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease. Am Heart J (2002) 0.80
Does hormone-replacement therapy prevent fractures in early postmenopausal women? J Bone Miner Res (2002) 0.80
A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. Br J Obstet Gynaecol (1999) 0.79
Postmenopausal hormone replacement therapy use decreases oxidative protein damage. Gynecol Obstet Invest (2002) 0.79
The effect of 17beta-estradiol and alpha-tocopherol on the oxidation of LDL cholesterol from postmenopausal women and the minor effect of gamma-tocopherol and melatonin. Menopause (2000) 0.78
Estradiol reduces F2alpha-isoprostane production in cultured human endothelial cells. Am J Physiol Heart Circ Physiol (2002) 0.78
The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis (2002) 0.78
Can menopausal hormone therapy prevent coronary heart disease? Trends Endocrinol Metab (2008) 0.78
Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause. Am J Crit Care (2001) 0.77
Influence of 17beta-oestradiol on blood pressure of postmenopausal women at high vascular risk. J Hypertens (2001) 0.77
Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J (2006) 0.76
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA (2012) 6.96
Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA (2008) 6.50
Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med (2008) 5.86
Racial differences in incident heart failure among young adults. N Engl J Med (2009) 5.60
Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med (2002) 5.42
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. J Cardiovasc Comput Tomogr (2009) 4.66
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2010) 4.56
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med (2010) 4.42
Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol (2003) 4.28
Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry (2010) 4.27
An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med (2015) 4.18
Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol (2004) 4.03
The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med (2006) 3.93
From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol (2006) 3.82
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
Frequency of stress testing to document ischemia prior to elective percutaneous coronary intervention. JAMA (2008) 3.62
Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med (2014) 3.57
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health (2005) 3.33
Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int (2010) 3.23
Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging (2009) 3.23
Support from hospital to home for elders: a randomized trial. Ann Intern Med (2014) 3.21
Recommendations for intrauterine contraception: a randomized trial of the effects of patients' race/ethnicity and socioeconomic status. Am J Obstet Gynecol (2010) 3.18
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Modelling clustered survival data from multicentre clinical trials. Stat Med (2004) 3.02
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc (2005) 3.02
Food insecurity is associated with diabetes mellitus: results from the National Health Examination and Nutrition Examination Survey (NHANES) 1999-2002. J Gen Intern Med (2007) 3.01
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol (2012) 3.01
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA (2002) 2.91
Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg (2009) 2.89
Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging (2009) 2.86
The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med (2004) 2.86
Effect of awareness of language law on language access in the health care setting. J Gen Intern Med (2006) 2.82
Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol (2002) 2.81
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil Steril (2005) 2.77
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev (2012) 2.71
Noninvasive fractional flow reserve derived from computed tomography angiography for coronary lesions of intermediate stenosis severity: results from the DeFACTO study. Circ Cardiovasc Imaging (2013) 2.68
HIV infection and bone mineral density in middle-aged women. Clin Infect Dis (2006) 2.67
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol (2010) 2.63
Assisted reproductive technology practice patterns and the impact of embryo transfer guidelines in the United States. Fertil Steril (2007) 2.61
Sexual activity and function in middle-aged and older women. Obstet Gynecol (2006) 2.59
HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet (2002) 2.59
Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril (2004) 2.57
A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol (2003) 2.57
Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis (2005) 2.55
A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54
Weight loss: a novel and effective treatment for urinary incontinence. J Urol (2005) 2.52
Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med (2008) 2.49
Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med (2014) 2.48
Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab (2003) 2.47
Radiation reduction with prospective ECG-triggering acquisition using 64-multidetector Computed Tomographic angiography. Int J Cardiovasc Imaging (2008) 2.43
Pelvic organ prolapse surgery in the United States, 1997. Am J Obstet Gynecol (2002) 2.43
Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care (2007) 2.39
Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr (2004) 2.39
Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med (2013) 2.38
Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med (2010) 2.37
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium. Biol Reprod (2009) 2.26
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol (2012) 2.23